The most advanced of these agents, the dipeptide boronic acid M358 (Merck KGaA), showed >300-fold selectivity for LMP7 versus β5 and compelling activity in preclinical models of multiple myeloma [28,29]. The gene discussed is PSMB8; the disease is plasma cell myeloma.